{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T22:27:44Z","timestamp":1771367264357,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The introduction of CFTR modulator therapies (CFTRmt) has changed cystic fibrosis (CF) management. By improving airway rheology and function in people with CF (pwCF), CFTRmt are expected to modify cyto-microbiological features. This French multicentre study aimed to assess changes in airway fungal ecology before and during the CFTRmt era. Data from pwCF followed at CF reference centres in Besan\u00e7on, Bordeaux, Limoges, and Rennes were collected before CFTRmt use (2014) and after their widespread implementation (2022), including elexacaftor\/tezacaftor\/ivacaftor (ETI) as well as other CFTR modulator therapies used in France. Mycological outcomes included the total number of yearly cultures and the number of positive cultures per fungus and per patient, regardless of CFTRmt. A total of 1555 and 1400 sputum samples from 438 and 483 pwCF were analysed in 2014 and 2022, respectively. The 2022 population was significantly older, in agreement with French ETI-prescription limited to pwCF aged at least 12 in 2022. Regardless of year, patients with positive fungal cultures were older than those with negative ones. Positive cultures for Aspergillus section Fumigati significantly decreased under CFTRmt at both population and individual levels. Conversely, positive cultures for Aspergillus section Nigri, Penicillium sp., and Candida albicans increased under CFTRmt, in correlation with the type of CFTRmt for Aspergillus section Nigri. CFTR modulators appear to modify the airway mycobiome and fungal ecology depending on CFTRmt type. Among several factors that may account for these mycobiome changes between 2014 and 2022, environmental changes, including climate-related shifts in Aspergillus distribution, may contribute potentially.<\/jats:p>","DOI":"10.1093\/mmy\/myag011","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:31:48Z","timestamp":1770121908000},"source":"Crossref","is-referenced-by-count":0,"title":["Changes in the fungal ecology in the era of CFTR modulators: Results from a French multicentre study focused on cystic fibrosis airways"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1645-0030","authenticated-orcid":false,"given":"Maxime","family":"Lefranc","sequence":"first","affiliation":[{"name":"University Hospital of Bordeaux, University of Bordeaux Mycology-Parasitology Department, , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Herault","sequence":"additional","affiliation":[{"name":"University Hospital of Limoges, University of Limoges Mycology-Parasitology Department, , Limoges ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4144-476X","authenticated-orcid":false,"given":"Anne-Pauline","family":"Bellanger","sequence":"additional","affiliation":[{"name":"University Hospital of Besan\u00e7on, University of Besan\u00e7on Mycology-Parasitology Department, , Besan\u00e7on ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Guegan","sequence":"additional","affiliation":[{"name":"University Hospital of Rennes, Chronic Aspergillosis National Reference Center, European Excellence Center in Medical Mycology (ECMM-EC), University of Rennes , Rennes ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Imbert","sequence":"additional","affiliation":[{"name":"University Hospital of Bordeaux, University of Bordeaux Mycology-Parasitology Department, , Bordeaux ,","place":["France"]},{"name":"University Hospital of Bordeaux, Chronic Aspergillosis National Reference Center, University of Bordeaux , Bordeaux ,","place":["France"]},{"name":"Inserm U1045, CTCB, University of Bordeaux , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Enaud","sequence":"additional","affiliation":[{"name":"Inserm U1045, CTCB, University of Bordeaux , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Bui","sequence":"additional","affiliation":[{"name":"Inserm U1045, CTCB, University of Bordeaux , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Gabriel","sequence":"additional","affiliation":[{"name":"University Hospital of Bordeaux, University of Bordeaux Mycology-Parasitology Department, , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Accoceberry","sequence":"additional","affiliation":[{"name":"University Hospital of Bordeaux, University of Bordeaux Mycology-Parasitology Department, , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Y\u00e9ra","sequence":"additional","affiliation":[{"name":"University Hospital of Limoges, University of Limoges Mycology-Parasitology Department, , Limoges ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emeline","family":"Scherer","sequence":"additional","affiliation":[{"name":"University Hospital of Besan\u00e7on, University of Besan\u00e7on Mycology-Parasitology Department, , Besan\u00e7on ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Vallet","sequence":"additional","affiliation":[{"name":"University of Brest - Faculty of Medicine, Inserm UMR1078, University Hospital Brest , Brest ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"H\u00e9ry-Arnaud","sequence":"additional","affiliation":[{"name":"University of Brest - Faculty of Medicine, Inserm UMR1078, University Hospital Brest , Brest ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Gangneux","sequence":"additional","affiliation":[{"name":"University Hospital of Rennes, Chronic Aspergillosis National Reference Center, European Excellence Center in Medical Mycology (ECMM-EC), University of Rennes , Rennes ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Delhaes","sequence":"additional","affiliation":[{"name":"University Hospital of Bordeaux, University of Bordeaux Mycology-Parasitology Department, , Bordeaux ,","place":["France"]},{"name":"University Hospital of Bordeaux, Chronic Aspergillosis National Reference Center, University of Bordeaux , Bordeaux ,","place":["France"]},{"name":"Inserm U1045, CTCB, University of Bordeaux , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2026021716313490400_bib1","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"2026021716313490400_bib2","doi-asserted-by":"publisher","first-page":"e0225122","DOI":"10.1128\/spectrum.02251-22","article-title":"Effects of lumacaftor-ivacaftor on airway microbiota\u2013mycobiota and inflammation in patients with cystic fibrosis appear to be linked to Pseudomonas aeruginosa chronic colonization","volume":"11","author":"Enaud","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026021716313490400_bib3","doi-asserted-by":"publisher","first-page":"240068","DOI":"10.1183\/16000617.0068-2024","article-title":"Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy","volume":"33","author":"Milczewska","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2026021716313490400_bib4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026021716313490400_bib5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jcf.2018.10.001","article-title":"Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: results from the international prospective study \u201cMFIP\u201d","volume":"18","author":"Delhaes","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026021716313490400_bib6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12890-022-02054-3","article-title":"Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization\u2014a registry-based case-control study","volume":"22","author":"Blomquist","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026021716313490400_bib7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/MCP.0000000000000921","article-title":"Progress and challenges in fungal lung disease in cystic fibrosis","volume":"28","author":"Hong","year":"2022","journal-title":"Curr Opin Pulm Med."},{"key":"2026021716313490400_bib8","doi-asserted-by":"publisher","first-page":"2400803","DOI":"10.1183\/13993003.00803-2024","article-title":"Fungal lung disease","volume":"64","author":"Jaggi","year":"2024","journal-title":"Eur Respir J."},{"key":"2026021716313490400_bib9","doi-asserted-by":"publisher","first-page":"100294","DOI":"10.1016\/j.jacig.2024.100294","article-title":"Allergic bronchopulmonary aspergillosis as an initial manifestation of cystic fibrosis: diagnostic and therapeutic implications in the era of CFTR modulators","volume":"3","author":"Mitropoulou","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"2026021716313490400_bib10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"key":"2026021716313490400_bib11","doi-asserted-by":"publisher","first-page":"2102861","DOI":"10.1183\/13993003.02861-2021","article-title":"Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor","volume":"61","author":"Zhang","year":"2023","journal-title":"Eur Respir J."},{"key":"2026021716313490400_bib12","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3390\/ijms23073513","article-title":"The effect of CFTR modulators on airway infection in cystic fibrosis","volume":"23","author":"Harvey","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026021716313490400_bib13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"2026021716313490400_bib14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin Infect Dis."},{"key":"2026021716313490400_bib15","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1513\/AnnalsATS.201902-122OC","article-title":"Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using National Registry Data","volume":"16","author":"Frost","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2026021716313490400_bib16","doi-asserted-by":"publisher","first-page":"18999","DOI":"10.1038\/s41598-020-75886-w","article-title":"Risk factors for respiratory Aspergillus fumigatus in German cystic fibrosis patients and impact on lung function","volume":"10","author":"D\u00fcesberg","year":"2020","journal-title":"Sci Rep"},{"key":"2026021716313490400_bib17","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jcf.2022.09.007","article-title":"Advent of elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis treatment: what consequences on Aspergillus-related diseases? Preliminary insights","volume":"21","author":"Chesnay","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026021716313490400_bib18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1055\/s-0042-1759882","article-title":"Clinical relevance of fungi in cystic fibrosis","volume":"44","author":"Schwarz","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2026021716313490400_bib19","doi-asserted-by":"publisher","first-page":"17534666241254090","DOI":"10.1177\/17534666241254090","article-title":"Impact of lumacaftor\/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden","volume":"18","author":"Al\u00a0Shakirchi","year":"2024","journal-title":"Ther Adv Respir Dis"},{"key":"2026021716313490400_bib20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00408-024-00781-4","article-title":"Respiratory outcomes and Aspergillus serology following elexacaftor\/tezacaftor\/ivacaftor therapy in people with cystic fibrosis and a history of Aspergillus fumigatus infection","volume":"203","author":"Lanfranchi","year":"2025","journal-title":"Lung"},{"key":"2026021716313490400_bib21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor\u2013tezacaftor\u2013deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026021716313490400_bib22","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1128\/JCM.00213-11","article-title":"Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance","volume":"49","author":"Mortensen","year":"2011","journal-title":"J Clin Microbiol."},{"key":"2026021716313490400_bib23","doi-asserted-by":"publisher","first-page":"759944","DOI":"10.3389\/fcimb.2021.759944","article-title":"Meteorological factors influence the presence of fungi in the air; a 14-month surveillance study at an adult cystic fibrosis center","volume":"11","author":"Van\u00a0Rhijn","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2026021716313490400_bib24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.21203\/rs.3.rs-2846739\/v1","article-title":"The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis","volume-title":"Allergy Asthma Clin Immunol.","author":"Mehta","year":"2023"},{"key":"2026021716313490400_bib25","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jcf.2023.02.003","article-title":"Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis","volume":"22","author":"Hong","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026021716313490400_bib26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1164\/rccm.202406-1128RL","article-title":"Elexacaftor\/tezacaftor\/ivacaftor markedly reduces Aspergillus fumigatus in cystic fibrosis","volume":"210","author":"Morgan","year":"2024","journal-title":"Am J Respir Crit Care Med."},{"key":"2026021716313490400_bib27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fcimb.2020.00372","article-title":"CFTR modulators dampen Aspergillus-induced reactive oxygen species production by cystic fibrosis phagocytes","volume":"10","author":"Currie","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2026021716313490400_bib28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s11046-021-00541-5","article-title":"CF fungal disease in the age of CFTR modulators","volume":"186","author":"Bercusson","year":"2021","journal-title":"Mycopathologia"},{"key":"2026021716313490400_bib29","doi-asserted-by":"publisher","first-page":"e0151623","DOI":"10.1128\/mbio.01516-23","article-title":"The cystic fibrosis treatment trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms","volume":"14","author":"Jones","year":"2023","journal-title":"mBio"},{"key":"2026021716313490400_bib30","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1007\/s00253-021-11407-7","article-title":"Drug repurposing strategies in the development of potential antifungal agents","volume":"105","author":"Zhang","year":"2021","journal-title":"Appl Microbiol Biotechnol."},{"key":"2026021716313490400_bib31","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-6545782\/v1","article-title":"Climate change-driven geographical shifts in Aspergillus species habitat and the implications for plant and human health","volume-title":"iScience","author":"Rhijn","year":"2025"},{"key":"2026021716313490400_bib32","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2147\/IDR.S267219","article-title":"Managing fungal infections in cystic fibrosis patients: challenges in clinical practice","volume":"14","author":"Magee","year":"2021","journal-title":"Infect Drug Resist"},{"key":"2026021716313490400_bib33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/mmy\/myz133","article-title":"Molecular epidemiology of Aspergillus species and other moulds in respiratory samples from Argentinean patients with cystic fibrosis","volume":"58","author":"Devoto","year":"2020","journal-title":"Med Mycol"},{"key":"2026021716313490400_bib34","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.2169\/internalmedicine.6305-20","article-title":"Successful treatment of antifungal combination therapy with inhaled liposomal amphotericin B and oral voriconazole for intractable chronic progressive pulmonary aspergillosis","volume":"60","author":"Hamada","year":"2021","journal-title":"Intern Med."},{"key":"2026021716313490400_bib35","doi-asserted-by":"publisher","first-page":"myad089","DOI":"10.1093\/mmy\/myad089","article-title":"Antifungal susceptibility patterns for Aspergillus, Scedosporium, and Exophiala isolates recovered from cystic fibrosis patients against amphotericin B, and three triazoles and their impact after long-term therapies","volume":"61","author":"Brito\u00a0Devoto","year":"2023","journal-title":"Med Mycol"},{"key":"2026021716313490400_bib36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/jof11030210","article-title":"Aspergillus in children and young people with cystic fibrosis: a narrative review","volume":"11","author":"Chesshyre","year":"2025","journal-title":"J Fungi"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myag011\/66788495\/myag011.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/64\/2\/myag011\/66788495\/myag011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/64\/2\/myag011\/66788495\/myag011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:31:41Z","timestamp":1771363901000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myag011\/8465385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myag011","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,2]]},"article-number":"myag011"}}